Burton Takes Lead At AAM’s Biosimilars Council
Policy Head Also Adds Strategic Alliances To Role As Simmon Moves To Lead FDLI
Craig Burton is stepping up to become executive director of the US Association for Accessible Medicines’ Biosimilars Council, as Christine Simmon has moved on to become president and CEO of the Food and Drug Law Institute. At the same time, Burton has added oversight of strategic alliances to his existing policy role with the AAM.
You may also be interested in...
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
Neuraxpharm has nabbed its second Almirall ex-employee in recent weeks, appointing Alfredo Barón as its new country manager for Spain. Plus, multiple trade groups expand their ranks and Perrigo promotes Alison Ives to chief scientific officer.
Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.